Swiss National Bank Sells 15,300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Swiss National Bank lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 306,300 shares of the biopharmaceutical company's stock after selling 15,300 shares during the quarter. Swiss National Bank owned 0.28% of Regeneron Pharmaceuticals worth $218,187,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. Amundi raised its position in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock worth $495,639,000 after purchasing an additional 22,538 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock valued at $215,562,000 after purchasing an additional 1,108 shares during the period. Finally, Candriam S.C.A. increased its stake in Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Candriam S.C.A. now owns 261,498 shares of the biopharmaceutical company's stock valued at $186,273,000 after purchasing an additional 8,973 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on REGN. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Robert W. Baird dropped their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 5th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $973.13.

Remove Ads

Regeneron Pharmaceuticals Trading Down 1.3 %

NASDAQ:REGN opened at $680.61 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm's 50 day moving average is $695.93 and its 200 day moving average is $840.01. The stock has a market capitalization of $74.41 billion, a PE ratio of 17.78, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $11.86 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.52%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.